calcipotriol/betamethasone dipropionate / Generic mfg. - LARVOL DELTA

BI05 Cemiplimab toes: a new entity in the expanding spectrum of immune checkpoint inhibitor skin toxicities. (PubMed, Br J Dermatol) - "As pain was severe, the initial concern was of a vasculitic process and oncology started prednisolone 2 mg kg-1 per day (120 mg per day) and flucloxacillin, with symptoms improving rapidly...Although she responded well to oral steroids and suspending cemiplimab, her skin flared with subsequent cycles with prednisolone doses below 10 mg per day despite topical treatment with clobetasol propionate, tacrolimus and calcipotriol-betamethasone ointments, fludroxycortide tape, Fucibet cream and potassium permanganate soaks...Clinically some features were reminiscent of 'COVID toes', but the underlying mechanism is unknown. This case of 'cemiplimab toes' is a striking reminder of the ever-evolving spectrum of cutaneous irAEs associated with immunotherapy and the challenges in diagnosing and managing these effectively to mitigate morbidity while continuing oncological treatment."

Checkpoint inhibition • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Hematological Disorders • Immunology • Myositis • Non-melanoma Skin Cancer • Novel Coronavirus Disease • Oncology • Pain • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Vasculitis

Indirect Comparison of Cal/BDP PAD-Cream vs Cal/BDP Foam in Patients with Plaque Psoriasis Meeting the Rule of Tens. (PubMed, Dermatol Ther (Heidelb)) - "In this ITC analysis, no significant differences in the clinical efficacy of Cal/BDP PAD cream and Cal/BDP foam in patients with plaque psoriasis meeting the Rule of Tens were observed considering their recommended treatment durations."

Journal • Dermatology • Immunology • Psoriasis

Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational Study. (PubMed, Clin Exp Dermatol) - "Though rarely, psoriasis and SpA are AEs emerging during dupilumab or tralokinumab therapy in AD patients. Close monitoring and prompt differential diagnosis is essential to optimize patient outcomes."

Journal • Observational data • Ankylosing Spondylitis • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab. (PubMed, Front Immunol) - "Previous treatment with topical corticosteroids, Calcipotriol Betamethasone Ointment and acitretin provided poor control of psoriasis, resulting in significant quality-of-life impairment. Xeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations."

Journal • Colorectal Cancer • Dermatology • Hepatitis B • Hidradenitis Suppurativa • Immunology • Infectious Disease • Oncology • Psoriasis • Solid Tumor • IL17A

Impact of long-term topical treatment on patient outcomes in patients with psoriasis (EADV 2025) - "The various topical drug categories are grouped on the X-axis as calcipotriol, tacalcitol, calcipotriol/betamethasone and different topical corticosteroids. Long-term use of topical treatments provides clinically meaningful improvements in psoriasis severity and quality of life. Proactive therapy reduces relapse rates, and adherence support enhances outcomes. Topical agents containing corticosteroids and/or vitamin D analogues are effective and well tolerated for extended use in patients with mild-to-severe psoriasis."

Clinical • Dermatology • Immunology • Psoriasis

Nail Psoriasis:Clinical Study and Therapeutic Efficacy (EADV 2025) - "Additionally, 15 out of 16 patients treated with calcipotriol and betamethasone showed partial improvement at 3 months, with a borderline statistical association (p = 0.043)...An additional 8 patients received methotrexate after previous treatment failure; all showed partial improvement at 3 months, with 6 achieving excellent improvement by 6 and 9 months. 4 patients were treated with Acitretin,2 showed partial improvement at 3 months, which remained stable over time... Nail psoriasis is a frequent manifestation of psoriasis that significantly affects quality of life. Wide range of treatment options exists, but management should be tailored to each patient due to the variability in clinical presentation and treatment response."

Clinical • Dermatology • Hematological Disorders • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Biological therapy enhances microvascular reactivity in psoriasis via improved endothelial function: a pilot study (EADV 2025) - "Materials & This cross-sectional pilot study involved 41 psoriasis patients who received topical therapy (PV-local; betamethasone or betamethasone-calcipotriol combination), 12 psoriasis patients who received anti- IL17 and anti-IL23 biological therapy (PV-biological), and 30 age- and sex-matched healthy controls. Laser Doppler flowmetry was used to measure microvascular reactivity in response to vascular occlusion (PORH) and iontophoresis of acetylcholine (AChID), as indicators of endothelium-dependent vasodilation, and in response to iontophoresis of sodium nitroprusside (SNPID), as an indicator of endothelium-independent vasodilation... Psoriasis patients on topical therapy alone tended to have attenuated endothelium-dependent vasodilation and increased serum fibrinogen levels compared with those treated with biological therapy. Larger, well-designed studies are needed to confirm the long-term vascular benefits of biological therapies in psoriasis."

Clinical • Atherosclerosis • Cardiovascular • Dermatology • Immunology • Inflammation • Psoriasis • CRP • IL17A

Tiny Tracks: A Rare Pediatric Presentation of Linear Psoriasis (EADV 2025) - "Initial management included a combination of betamethasone and calcipotriol ointment, emollients, and antihistamines, which resulted in notable clinical improvement, characterized by reduced erythema, scaling, and lesion size... This case highlights the diagnostic challenge of linear psoriasis in pediatrics and the importance of considering it in unilateral, Blaschkoid eruptions. Thorough history and physical examination, as well as attaining a sample for biopsy, are key to diagnosis, and early treatment can lead to significant clinical improvement. Awareness of this rare presentation can prevent misdiagnosis and unnecessary interventions."

Clinical • Anesthesia • Dermatology • Immunology • Pediatrics • Pruritus • Psoriasis • Pustular Psoriasis • Rare Diseases

Incremental medication adherence results in incremental improvement in S-mPASI and Worst Itch scores among patients with mild-to-moderate scalp psoriasis treated with calcipotriol and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) in routine clinical practices in Europe. Results from mixed-effect models in PRO-SCALP study. (EADV 2025) - "In real-world clinical practice settings, adherence to CAL/BPD PAD cream had a significant impact on patient clinical outcomes. Improved outcomes in scalp psoriasis may be achievable through interventions that improve patients' adherence to treatment."

Adherence • Clinical • Dermatology • Immunology • Pruritus • Psoriasis

Relationship between patient reported outcomes (PROs) and clinician reported outcomes (ClinROs) and treatment adherence, among patients treated with calcipotriol and betamethasone dipropionate cream with PAD technology (CAL/BDP PAD cream) among patients with mild-to-moderate scalp psoriasis in clinical practices in Europe: Final analysis of PRO-SCALP study. (EADV 2025) - "In real-world settings in Europe, patients with mild-to-moderate scalp psoriasis using CAL/BDP PAD cream experienced substantial improvements in PROs and ClinROs, with the high-adherence-group experiencing, overall, significantly better outcomes."

Adherence • Clinical • Patient reported outcomes • Dermatology • Immunology • Psoriasis

Impact of calcipotriol and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) on patient symptoms, functioning, and emotions among patients with mild-to-moderate scalp psoriasis in routine clinical practices in Europe. Final analysis of PRO-SCALP study. (EADV 2025) - "In real-world clinical practice settings in Europe, patients with mild-to-moderate scalp psoriasis using CAL/BPD PAD cream reported significant improvement in disease symptoms, functioning and emotional well- being."

Clinical • Dermatology • Immunology • Psoriasis

Highlighting the value of CAL/BDP PAD cream in patients meeting the Rule of 10s: Indirect treatment comparison with CAL/BDP foam in plaque psoriasis (EADV 2025) - P3 | "Introduction & Objectives: Calcipotriol/betamethasone dipropionate (CAL/BDP) poly-aphron dispersion (PAD technology) cream has already demonstrated significantly higher efficacy against CAL/BDP gel in patients with plaque psoriasis meeting the Rule of 10s criteria1... CAL/BDP PAD cream shows comparable efficacy and quality of life outcomes to CAL/BDP foam in the treatment of patients with plaque psoriasis meeting the Rule of 10s, that is, who have a more severe profile."

Clinical • Dermatology • Immunology • Psoriasis

Best responders to calcipotriol/betamethasone dipropionate (CAL/BDP) PAD-cream: six case reports of patients with mild-to-moderate plaque psoriasis (EADV 2025) - P3 | "We present six case reports demonstrating the efficacy of CAL/BDP PAD-cream in treating mild-to- moderate psoriasis while improving patients' quality of life. Despite the existing variability in key baseline characteristics, this entire group of patients reached the restrictive best response composite endpoint, which combines two efficacy outcomes (PGA and mPASI) and one quality of life outcome (DLQI) after 8 weeks of treatment. Furthermore, two of them showed an early response after only 4 weeks of treatment with CAL/BDP PAD-cream."

Case report • Clinical • Dermatology • Immunology • Psoriasis

Effectiveness and quality of life improvements with a fixed-dose combination of calcipotriol and betamethasone dipropionate cream in patients with mild to moderate psoriasis: real-world evidence (EADV 2025) - "In this real-world cohort, treatment with a fixed-dose combination of calcipotriol and betamethasone dipropionate cream led to rapid and significant clinical improvement and substantial enhancement in quality of life, displaying a favorable safety profile. These findings support its use as a first-line topical therapy for mild-to- moderate psoriasis, including in patients with comorbidities and difficult-to-treat areas, while also reducing treatment burden due to its once-daily application regimen."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Dermatology • Immunology • Obesity • Psoriasis

Rupioid psoriasis of the scalp: A pediatric case (EADV 2025) - "The patient was treated with a topical regimen combining betamethasone and salicylic acid, followed by betamethasone and calcipotriene, resulting in significant improvement... This case highlights a rare presentation of rupioid psoriasis in a pediatric patient, with an unusual scalp localization. The coexistence of retroauricular inverse psoriasis and nail involvement provided essential diagnostic clues that helped establish the correct diagnosis. This underscores the importance of a meticulous clinical and dermoscopic examination, particularly in children presenting with atypical hyperkeratotic scalp lesions."

Clinical • Dermatology • Immunology • Infectious Disease • Pediatrics • Psoriasis • Sarcoidosis

Persistent Vesiculopustular Eruption of Inflammatory Bowel Disease (VPE-IBD) on the scalp that responded to intravenous immunoglobulins and retinoids - A Challenging Case (EADV 2025) - "The patient received antibiotic therapy (IV Ciprofloxacin, p.os Clindamycin 300mgx2 /d for 4 weeks) and antifungal therapy (Itraconazole 200mg/d for 7 weeks) with topical and systemic corticosteroids gradually reduced from 30mg/day...Due to another relapse shortly after the first IvIG infusion,oral isotretinoin 20mg/d was added with a slow dosage reduction and topical combinations of calcipotriol/ betamethasone diproprionate 0.5% and erythromycin/benzoyl peroxide... This is a very rare case as ulcerative colitis was in remission despite the intense dermatological clinical picture, making the treatment challenging. The use of intravenous immunoglobulin with oral retinoids and concomitant topical therapy of calipotriol/corticosteroid/benzoyl peroxide proved to be an effective combination for the treatment of the patient. This combination has not been previously reported in the literature for the corresponding dermatological entity."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pneumonia • Ulcerative Colitis • IL17A • IL22

Durvalumab's cutaneous footprint: a refractory lichenoid eruption (EADV 2025) - "The chemotherapy regimen included cisplatin– vinorelbine, followed by maintenance therapy with durvalumab for one year...Treatment was initiated with calcipotriol/betamethasone, followed by maintenance therapy with topical tacrolimus 1%... Lichenoid reactions are a recognized dermatologic toxicity of immune checkpoint inhibitors, including PD-1 and PD-L1 inhibitors. However, literature specifically linking lichenoid eruptions to durvalumab remains scarce. Although these reactions can be asymptomatic, severe forms such as bullous lichenoid eruptions have been reported, which can lead to significant morbidity and may necessitate treatment interruption."

Dermatology • Immunology • Inflammatory Arthritis • Lichen Planus • Lung Adenocarcinoma • Lung Cancer • Lupus • Non Small Cell Lung Cancer • Solid Tumor • Urothelial Cancer

Linear Psoriasis Following Trauma in a Young Adult: A Case Report (EADV 2025) - "Despite treatment with high-potency topical corticosteroids, topical calcipotriol/betamethasone, and oral methotrexate (20 mg/week for six months), she showed minimal improvement. This case reinforces the importance of recognizing LP in adult patients presenting with Blaschkoid lesions and highlights ustekinumab as a viable therapeutic option in refractory cases. Increased awareness may prevent misdiagnosis and unnecessary treatments."

Case report • Clinical • Dermatology • Immunology • Mood Disorders • Pruritus • Psoriasis • Rare Diseases

LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 2025 (Businesswire) - "Highlights from EADV 2025 includes exciting phase 3 data in biologic injectables as well as foam and cream formulations, illustrating the breadth of therapeutic approaches represented in LEO Pharma’s medical dermatology portfolio....Notably, for the second year in a row, LEO Pharma is noted for 5 late-breaking presentations – corresponding to roughly 1 in 7 out of the possible 36 EADV late-breakers..."

Clinical data • Late-breaking abstract • Atopic Dermatitis • Dermatology • Psoriasis

Line-Field Confocal OCT and Clinical Correlation in Plaque Psoriasis Treated with Calcipotriol/Betamethasone Dipropionate and Polyaphron Dispersion Technology. (PubMed, Dermatol Pract Concept) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis. (PubMed, J Drugs Dermatol) - "Mean scores for PASI, PGA, BSA, and dermatology life quality index (DLQI) in patients with PASI 24-75 at week 8 improved by 83%, 52%, 78%, and 74%, respectively, from baseline with 4 weeks of C/BD add-on therapy (week 12); improvements were maintained up to week 24. Few patients experienced adverse events (AEs), and none had serious AEs or discontinued due to AEs."

Clinical • Journal • Dermatology • Immunology • Psoriasis

Pulsed Dye, Fractional CO2, and Nd:YAG Lasers: A Comprehensive Evaluation in the Management of Nail Psoriasis. (PubMed, J Lasers Med Sci) - "The participants were divided into four groups: Nd:YAG laser, PDL, fractional CO2 laser, and a control group treated with calcipotriol/betamethasone ointment...These findings endorse the inclusion of laser therapy in management plans for nail psoriasis, suggesting further research into optimizing their use and potential combination with other therapies. Trial Registration: https://irct.behdasht.gov.ir/; identifier: IRCT20220723055530N4."

Clinical • Journal • Dermatology • Immunology • Pain • Psoriasis

Linear psoriasis or ILVEN? A pediatric case unraveling the mosaic puzzle. (PubMed, Dermatol Reports) - "The patient showed rapid improvement with topical calcipotriol/betamethasone, followed by long-term remission...Few pediatric cases in the literature have documented such a long and stable evolution, making this report a valuable contribution to the distinction between LP and ILVEN. The case highlights the importance of integrating clinical, histological, and longitudinal data when evaluating linear dermatoses in children."

Journal • Dermatology • Immunology • Pediatrics • Psoriasis • Rare Diseases

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa-case report, review of the literature and multidisciplinary clinical practice recommendations. (PubMed, Ther Adv Hematol) - "Ropeginterferon alfa-2b has been approved for patients with polycythemia vera (PV) with no symptomatic splenomegaly as first-line cytoreductive therapy, based on the results of the PROUD-PV/CONTINUATION-PV studies, documenting significantly higher rates of complete hematologic response (CHR) compared with hydroxyurea from 2-year timepoint onward...The other patient developed widespread psoriatric skin lesions, which were treated with moderate effect with topical therapy with calcipotriene and betamethasone dipropionate foam, antidry calm lotion and in the course of the disease with ultraviolet light therapy (UVB). Only with methotrexate she achieved a nearly complete remission of the psoriasis...We review the pertinent literature on the management of interferon-mediated autoimmune diseases in patients with MPN. As there is little published evidence on that topic, we propose multidisciplinary clinical practice recommendations based on available evidence and clinical..."

Journal • Dermatology • Hematological Disorders • Immunology • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Psoriasis • Sarcoidosis

Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials. (PubMed, Dermatol Ther (Heidelb)) - P3 | "CAL/BDP PAD-cream demonstrated higher best response rates compared to CAL/BDP gel and vehicle in adults with mild-to-moderate psoriasis. Baseline DLQI and mPASI scores may predict which patients are most likely to achieve best response to CAL/BDP PAD-cream."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis